NEW YORK (GenomeWeb) – Fluidigm has announced that it has entered a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease researchers.
According to the partners, researchers will be able to expedite the design of disease-specific next-generation sequencing, genotyping, and real-time PCR panels using Fluidigm's automated microfluidic systems.
Genomenon has designed its Mastermind Panel Design Service to identify disease-specific biomarkers for researchers using the firm's genomic search database and automated machine-learning algorithms. Genomenon then delivers a group of prioritized candidates to researchers to help in panel design. The Ann Arbor, Michigan-based firm claims its service can minimize target identification time from a year to a few weeks.
"This valuable addition to our custom genomic panel design offering represents an important building block in expanding the benefits of microfluidics technology to a wider range of disease reach areas," Fluidigm CEO and President Chris Linthwaite said in a statement.
Financial details of the collaboration were not disclosed.
Genomenon previously announced a co-marketing agreement with Swift Biosciences in May to design and create targeted gene sequencing panels.